Lilly reports data for CETP inhibitor evacetrapib

Eli Lilly and Co. (NYSE:LLY) reported data from a Phase II trial of evacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, to treat patients with elevated LDL-C or low HDL-C. In 398 patients, the product given alone or in combination with statins (simvastatin, atorvastatin or rosuvastatin) led to significantly greater increases in HDL-C and significantly greater reductions in LDL-C, the co-primary endpoints, compared to placebo or statin monotherapy. ...